18f-fpprgd2 pet/ct or pet/mri in predicting early response in patients with cancer receiving anti-angiogenesis therapy

Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Male Breast Cancer; Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Adult Brain Tumor; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Hypopharyngeal Cancer; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Laryngeal Cancer; Recurrent Lip and Oral Cavity Cancer; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Nasopharyngeal Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Oropharyngeal Cancer; Recurrent Pancreatic Cancer; Recurrent Paranasal Sinus and Nasal Cavity Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Salivary Gland Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVA Salivary Gland Cancer; Stage IVB Colon Cancer; Stage IVB Salivary Gland Cancer; Stage IVC Salivary Gland Cancer; Tongue Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Summary: the purpose of the study is to conduct research of a new pet radiopharmaceutical in cancer patients. the uptake of the novel radiopharmaceutical 18f-fpprgd2 will be assessed in study participants with glioblastoma multiforme (gbm), gynecological cancers, and renal cell carcinoma (rcc) who are receiving antiangiogenesis treatment.

primary objective • evaluate 18f-fpprgd2 and 18f-fdg as pet/ct or pet/mri radiotracers for imaging prediction and assessment of response to anti-angiogenesis therapy in participants with glioblastoma multiforme (gbm), gynecological cancers, and renal cell carcinoma (rcc). secondary objective • progression-free survival (pfs) at up to 1 year after initial scans and treatment outline: patients undergo 18f-fpprgd2 and 18f-fdg pet/ct or pet/mri medical imaging at baseline and at regular medical care follow-up (6 to 12 weeks). after completion of study imaging, patients are followed up at 12 months.

Eligibility criteria:
inclusion criteria: * provides written informed consent * diagnosed with advanced nsclc, breast cancer, gbm or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis * able to remain still for duration of each imaging procedure (about one hour) exclusion criteria: * pregnant or nursing * contraindication to mri * history of renal insufficiency (only for mri contrast administration)